Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Abbott agreed to acquire Biocompatibles' stent business for $234.5 million, gaining the BiodivYsio drug-eluting stent franchise and complementing its in-house…
Abbott's $235M purchase includes royalties up to 6%, signaling a meaningful long-term commitment to the drug-eluting stent space alongside an outright asset…
BiodivYsio's phosphorylcholine polymer was being evaluated as a versatile carrier for multiple anti-restenotic agents and a VEGF gene-therapy stent —…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Announced March 18, 2002, Abbott Laboratories acquired the cardiovascular stent business of Biocompatibles International plc for approximately $235 million in cash. The FTC granted early termination of the antitrust waiting period on June 26, 2002.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Abbott Laboratories / Biocompatibles International plc (cardiovascular stent business) (this deal) | 2002 | $235M | — |
| Abbott Laboratories / Knoll Pharmaceutical Company (BASF Pharma) | 2001 | $6.9B | 100 |
| Abbott Laboratories / Knoll Pharmaceuticals (BASF Pharma) | 2000 | $6.9B | 95 |
| Abbott Laboratories / Alere Inc. | 2016 | $5.8B | 95 |
| Abbott Laboratories / St. Jude Medical | 2016 | $30.5B | 82 |
| Abbott Laboratories / TheraSense Inc. | 2004 | $1.2B | 81 |
| Abbott Laboratories / Vysis Inc. | 2001 | $355M | 79 |
← Browse all deals · How we score deals
More: 2002 deals · Abbott Laboratories deals · Cardiovascular deals